Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern

Parasitology Research

Volumn 112, Issue 3, 2013, Pages 1001-1009

  Mishra, Jyotsna ^a   Madhubala, Rentala ^b   Singh, Sarman ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; ANTIMONY GLUCONATE; MESSENGER RNA; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQP1 GENE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE; GENE CONTROL; GENE EXPRESSION; IC 50; IN VITRO STUDY; INDIA; LDMT GENE; LDROS3 GENE; LEISHMANIA DONOVANI; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PARASITE ISOLATION; PHENOTYPE; POST KALA AZAR DERMAL LEISHMANIASIS; PRIORITY JOURNAL; SKIN LEISHMANIASIS; STRAIN DIFFERENCE; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; AQUAPORIN 1; GENE EXPRESSION PROFILING; HUMANS; INDIA; INHIBITORY CONCENTRATION 50; LEISHMANIA DONOVANI; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MICROBIAL SENSITIVITY TESTS; PARASITIC SENSITIVITY TESTS;

LEISHMANIA DONOVANI; NASO HEXACANTHUS;

EID: 84878388707     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-012-3222-1     Document Type: Article

References (27)

1. Addy M, Nandy A (1992) Ten years of Kala-Azar in west Bengal, part I. Did post-Kala-Azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull World Health Organ 70:341-346
2. Ashutosh SS, Goyal N (2007) Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 56:143-153
3. Calvopina M, Gomez EA, Sindermann H, Cooper PJ, Hashiguchi Y (2006) Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. Am J Trop Med Hyg 75:1074-1077
4. de Oliveira JP, Fernandes F, Cruz AK, Trombela V, Monteiro E, Camargo AA, Barral A, de Oliveira CI (2007) Genetic diversity of Leishmania amazonensis strains isolated in northeastern Brazil as revealed by DNA sequencing, PCR-based analyses and molecular karyotyping. Kinetoplastid Biol Dis 6:5
5. Decuypere S, Rijal S, Yardley V, De DS, Laurent T, Khanal B, Chappuis F, Dujardin JC (2005) Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal. Antimicrob Agents Chemother 49:4616-4621
6. Dey A, Singh S (2007) Genetic heterogeneity among visceral and post-Kala-Azar dermal leishmaniasis strains from eastern India. Infect Genet Evol 7:219-222
7. Dutta A, Bandyopadhyay S, Mandal C, Chatterjee M (2005) Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis. Parasitol Int 54:119-122
8. El Tai NO, El FM, Mauricio I, Miles MA, Oskam L, El Safi SH, Presber WH, Schonian G (2001) Leishmania donovani: intraspecific polymorphisms of Sudanese isolates revealed by PCR-based analyses and DNA sequencing. Exp Parasitol 97:35-44
9. Gourbal B, Sonuc N, Bhattacharjee H, Legare D, Sundar S, Ouellette M, Rosen BP, Mukhopadhyay R (2004) Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem 279:31010-31017
10. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J (1999) Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341:1795-1800
11. Kumar D, Kulshrestha A, Singh R, Salotra P (2009) In vitro susceptibility of field isolates of Leishmania donovani to miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob Agents Chemother 53:835-838
12. Mandal S, Maharjan M, Singh S, Chatterjee M, Madhubala R (2010) Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India. J Antimicrob Chemother 65:496-507
13. Mishra M, Biswas UK, Jha DN, Khan AB (1992) Amphotericin versus pentamidine in antimony-unresponsive Kala-Azar. Lancet 340:1256-1257
14. Mishra J, Saxena A, Singh S (2007) Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem 14:1153-1169
15. Pandey BD, Pandey K, Kaneko O, Yanagi T, Hirayama K (2009) Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. Am J Trop Med Hyg 80:580-582
16. Perez-Victoria FJ, Sanchez-Canete MP, Castanys S, Gamarro F (2006) Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. J Biol Chem 281:23766-23775
17. Sanyal RK (1985) Leishmaniasis in the Indian subcontinent. In: Chang KP, Bray RS (eds) Leishmaniasis. Elsevier Science, Amsterdam, pp 443-467
18. V reducing activity correlates with antimony susceptibility in Leishmania donovani. J Biol Chem 276:3971-3976
19. Singh S, Sivakumar R (2004) Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother 10:307-315
20. Singh S, Chaudhry VP, Wali JP (1996) Transfusion-transmitted Kala-Azar in India. Transfusion 36:848-849
21. Singh S, Biswas A, Wig N, Aggarwal P, Sood R, Wali JP (1999) A new focus of visceral leishmaniasis in sub-Himalayan (Kumaon) region of northern India. J Commun Dis 31:73-77
22. Singh S, Sharma U, Mishra J (2011) Post-Kala-Azar dermal leishmaniasis: recent developments. Int J Dermatol 50:1099-1108
23. Sundar S, Olliaro PL (2007) Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther Clin Risk Manag 3:733-740
24. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31:1104-1107
25. Thakur CP, Kumar K (1992) Post Kala-Azar dermal leishmaniasis: a neglected aspect of Kala-Azar control programmes. Ann Trop Med Parasitol 86:355-359
26. Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Messick C, Olliaro P (2000) Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg 94:432-433
27. Zerpa O, Ulrich M, Blanco B, Polegre M, Avila A, Matos N, Mendoza I, Pratlong F, Ravel C, Convit J (2007) Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol 156:1328-1335